Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: A multicenter, controlled, randomized trial

被引:41
作者
Payen, JL
Izopet, J
Galindo-Migeot, V
Lauwers-Cances, V
Zarski, JP
Seigneurin, JM
Dussaix, E
Voigt, JJ
Selves, J
Barange, K
Puel, J
Pascal, JP
机构
[1] CHU Purpan, Serv Hepatogastroenterol, Toulouse, France
[2] CHU Purpan, Serv Virol, Toulouse, France
[3] CHU Purpan, Serv Epidemiol, Toulouse, France
[4] CHU Grenoble, Dept Hepatogastroenterol, F-38043 Grenoble, France
[5] CHU Grenoble, Lab Virol Med Mol, F-38043 Grenoble, France
[6] CHU, Serv Virol, Kremlin Bicetre, France
[7] Ctr Claudius Regaud, Serv Anat Pathol, Toulouse, France
[8] CHU Purpan, Serv Anat Pathol, Toulouse, France
关键词
D O I
10.1002/hep.510280631
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
We studied the efficacy of three interferon alfa-2b (IFN-alpha 2b) regimens for the retreatment of patients with chronic hepatitis C (CHC) with prior complete response followed by relapse. Consecutive patients with CHC who had a complete biochemical response but relapse after a first course of 6 months of IFN with 3 million units (MU) given subcutaneously three times per week were enrolled in the study. Six to 24 months after the end of the first treatment, the patients were randomly assigned to receive IFN with either the same regimen (group 1), a regimen of 12 months with 3 MU (group 2), or a regimen of 6 months with 10 MU (group 3). Sustained biochemical response was defined as normal serum alanine transaminase (ALT) values during the follow-up and sustained virological response as a clearance of hepatitis C virus (HCV) RNA from the serum at the end of follow-up (6 months' posttreatment). Histological improvement was defined as a decrease of 1 point in Metavir score between the first liver biopsy and a biopsy performed at 6 months' postretreatment. Two hundred forty-seven patients were randomized: 75 to group 1, 91 to group 2, and 81 to group 3. In an intent-to-treat analysis, 12%, 36.3%, and 18.5% of patients had a sustained biochemical response after retreatment in groups i, 2, and 3, respectively (P <.001); 13.8%, 32.4%, and 17.2% of patients had a sustained virological response after retreatment in groups i, 2, and 3, respectively (P <.05). A low viral load and patients in group 2 were independently associated with a sustained biochemical response. A low Knodell score index before treatment, patients with a high level of ALT before retreatment, genotype 3, low viral load, and patients in group 2 were independently associated with sustained virological response. Younger age, a high level of ALT, a low level of gamma-glutamyl transferase before retreatment, low viral load, and patients in group 2 were independently associated with sustained biochemical and virological response. Among the 80 patients with repeated liver biopsies, 47.6% had improved histological activity scores; this improvement was associated with a sustained biochemical and virological response. In patients with CHC initially treated with 3 MU of IFN given subcutaneously three times per week over a 6-month period, and who subsequently developed a relapse after a biochemical response, retreatment with a regimen of 3 MU of IFN given three times per week for 12 months produced better biochemical and virological sustained response rates than regimens involving a higher dose or a shorter duration of retreatment. The biochemical and virological sustained response was associated with histological improvement.
引用
收藏
页码:1680 / 1686
页数:7
相关论文
共 33 条
  • [1] ALBER MS, 1997, PROG NONLIN, V26, P1
  • [2] BEDOSSA P, 1994, HEPATOLOGY, V20, P15
  • [3] The effect of interferon on the liver in chronic hepatitis C: A quantitative evaluation of histology by meta-analysis
    Camma, C
    Giunta, M
    Linea, C
    Pagliaro, L
    [J]. JOURNAL OF HEPATOLOGY, 1997, 26 (06) : 1187 - 1199
  • [4] Therapy of hepatitis C: Meta-analysis of interferon alfa-2b trials
    Carithers, RL
    Emerson, SS
    [J]. HEPATOLOGY, 1997, 26 (03) : S83 - S88
  • [5] COMPARISON OF 1 OR 3 MU OF INTERFERON ALFA-2B AND PLACEBO IN PATIENTS WITH CHRONIC NON-A, NON-B HEPATITIS
    CAUSSE, X
    GODINOT, H
    CHEVALLIER, M
    CHOSSEGROS, P
    ZOULIM, F
    OUZAN, D
    HEYRAUD, JP
    FONTANGES, T
    ALBRECHT, J
    MESCHIEVITZ, C
    TREPO, C
    [J]. GASTROENTEROLOGY, 1991, 101 (02) : 497 - 502
  • [6] HEPATITIS-C SEROTYPE AND RESPONSE TO INTERFERON THERAPY
    CHEMELLO, L
    ALBERTI, A
    ROSE, K
    SIMMONDS, P
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (02) : 143 - 143
  • [7] Efficacy of a second cycle of interferon therapy in patients with chronic hepatitis C
    Chemello, L
    Cavalletto, L
    Donada, C
    Bonetti, P
    Casarin, P
    Urban, F
    Bernardinello, E
    Pontisso, P
    Alberti, A
    [J]. GASTROENTEROLOGY, 1997, 113 (05) : 1654 - 1659
  • [8] Re-treatment with interferon alfa of patients with chronic hepatitis C
    Chow, WC
    Boyer, N
    Pouteau, M
    Castelnau, C
    Martinot-Peignoux, M
    Martins-Amado, V
    Degos, F
    Maghinici, C
    Sinegre, M
    Benhamou, JP
    Degott, C
    Erlinger, S
    Marcellin, P
    [J]. HEPATOLOGY, 1998, 27 (04) : 1144 - 1148
  • [9] D'Aquino M., 1996, Hepatology, V24, p498A
  • [10] Davis G. L., 1997, Hepatology, V26, p247A